JGJianxin Guo

Jianxin Guo

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Jianxin Guo has a total of 23 co-authors. Here are the top co-authors by number of shared publications:

  • Zhongbing Wu

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang 050017, China

    4 shared publications
  • Jing Li

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang 050017, China

    3 shared publications
  • Jianfeng Yuan

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang, China

    2 shared publications
  • Chenchen Zhang

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang, China

    1 shared publication
  • Enzhen Wu

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang, China

    1 shared publication
  • Jianfeng Yuan

    College of Integrated Chinese and Western Medicine, Hebei Medical University, Shijiazhuang 050017, China

    1 shared publication

Latest Publications

  • Open Access

    Targeted Chemical Monitoring and Integrated Preclinical Evaluation of Zishui Qinggan Yin in 4-NQO-Induced Esophageal Precancer: Histopathological and PI3K/AKT/mTOR-Associated Changes

    by Yueheng Ouyang, Jianxin Guo, Jianfeng Yuan, Zhongbing Wu, Jing Li

    Esophageal squamous cell carcinoma frequently develops through a prolonged precancerous phase, creating an opportunity for intervention. Zishui Qinggan Yin (ZSQGY) is a multi-component botanical preparation, but its effects in esophageal precancer and its formulation-level chemical profile remain incompletely defined. We monitored a predefined 40-analyte panel by UPLC-Q Exactive/MS in three independently extracted aliquots from the same formulation batch administered to mice. A 4-nitroquinoline-1-oxide model was then evaluated by consensus histopathology, mouse-grouped whole-slide digital pathology, network-based target prioritization, molecular docking, exploratory drug affinity responsive target stability (DARTS), Western blotting, qPCR, and serial-section immunohistochemistry. Signals corresponding to 38 predefined analytes were reported. ZSQGY treatment was associated with a lower-grade lesion pattern in the evaluated mouse-level specimens. Exploratory DARTS was analyzed in two independent n = 6 tissue-background datasets. In the original 4-NQO model-background cohort, ex vivo ZSQGY (100 μg/mL) increased the AKT1-immunoreactive relative-protection signal in five of six lysates (mean 2.04 ± 1.15). In an additional cohort from mice that had received ZSQGY in vivo, ex vivo ZSQGY produced mean relative-protection values of 1.21, 1.75, and 1.92 at 50, 100, and 200 μg/mL, respectively. The nominal exact p value for the 100 μg/mL versus vehicle contrast in the additional exploratory dataset was 0.0313; This exploratory result should be interpreted cautiously. Neither dataset establishes direct binding or in vivo target occupancy. PI3K p110α DARTS was technically inconclusive. Endpoint tissues showed lower AKT, mTOR, S6K1, and 4E-BP1 phosphorylation, together with PTEN-associated changes, reduced Ki-67, increased cleaved caspase-3 staining, and selected downstream transcript changes, including a non-significant downward trend in PARP1. These findings support a preclinical association between ZSQGY treatment, attenuation of esophageal precancer progression, and AKT-centered PI3K/AKT/mTOR pathway modulation. They do not establish direct binding, in vivo target occupancy, pathway necessity, active constituents, or causal mediation.

  • Open Access

    The role of TRAF2 in pan-cancer revealed by integrating informatics and experimental validation

    by Xizheng Wang, Jianfeng Yuan, Chenchen Zhang, Lingyu Kong, Enzhen Wu, Jianxin Guo, Zhongbing Wu

    Background: Tumor necrosis factor (TNF) receptor associated factor-2 (TRAF2) is an E3 ubiquitin ligase and scaffolding protein that contribute to the progression of various malignant tumors. However, the role of TRAF2 expression in epigenetic, cancer prognosis, and immune responses in tumor microenvironment is unclear.Methods: We used The Human Protein Atlas (HPA) database, TIMER 2.0 database, and TCGA database to evaluate TRAF2 expression in human normal and tumor tissues. Correlation of TRAF2 expression with mutations and epigenetic in tumors was evaluated using the cBioPortal platform and the GSCA database. To assess the prognostic value of TRAF2, we performed Kaplan-Meier plots and Cox regression analysis. LinkedOmics database was used for PANTHER Pathways enrichment analysis. The relationship between TRAF2 expression and immune checkpoint genes, as well as immune cell infiltration, was examined using TIMER 2.0 and the R language. Single-cell sequencing data and multiple immunofluorescence staining were used to observe the co-expression of TRAF2 on hepatocellular carcinoma cells and immune cells. Furthermore, using siRNA-mediated knockdown, we explored the potential role of TRAF2 in liver cancer cell biology.Results: Our findings indicate that TRAF2 is frequently mutated and significantly overexpressed in various types of cancers, and this overexpression is linked to a poor prognosis. The epigenetic alterations in TRAF2 was significant across various types of cancers. TRAF2 is associated with the levels of various immune checkpoint genes and multiple tumor-infiltrating immune cells, suggesting its potential involvement in tumor microenvironment. Of note, enrichment analysis revealed a significant correlation between TRAF2 and T cell activation, and single-cell sequencing indicated that TRAF2 was overexpressed in malignant cells and T cells. In vivo results demonstrated that TRAF2 was closely associated with T lymphocytes in hepatocellular carcinoma. The results of our in vitro experimental studies confirmed that the loss of TRAF2 function inhibits the malignant behavior of HepG2 cells in hepatocellular carcinoma.Conclusion: TRAF2 represents a potential prognostic biomarker and therapeutic target for cancer immunotherapy, particularly in patients with hepatocellular carcinoma.

  • Open Access

    Network Pharmacology Analysis and In Vitro Validation of the Active Ingredients and Potential Mechanisms of Gynostemma Pentaphyllum Against Esophageal Cancer

    by Jianxin Guo, Zhongbing Wu, Xiaoyue Chang, Ming Huang, Yu Wang, Renping Liu, Jing Li

    Background: Esophageal cancer (EC) is one of the deadliest malignancies worldwide. Gynostemma pentaphyllum Thunb. Makino (GpM) has been used in traditional Chinese medicine as a treatment for tumors and hyperlipidemia. Nevertheless, the active components and underlying mechanisms of anti-EC effects of GpM remain elusive. Objective: This study aims to determine the major active ingredients of GpM in the treatment of EC and to explore their molecular mechanisms by using network pharmacology, molecular docking, and in vitro experiments. Methods: Firstly, active ingredients and potential targets of GpM, as well as targets of EC, were screened in relevant databases to construct a compound-target network and a protein-protein interaction (PPI) network that narrowed down the pool of ingredients and targets. This was followed by gene ontology (GO) functional and Kyoto Encyclopedia of Genes and Genomes (KEGG) pathway enrichment analyses. Next, molecular docking, ADME and toxicity risk prediction, cell viability assays, in vitro scratch assays, Transwell cell invasion assays, and Western blotting analysis were subsequently applied to validate the results of the network analysis. Results: The screening produced a total of 21 active ingredients and 167 ingredient-related targets for GpM, along with 2653 targets for EC. The PPI network analysis highlighted three targets of interest, namely AKT1, TP53, and VEGFA, and the compound-target network identified three possible active ingredients: quercetin, rhamnazin, and isofucosterol. GO and EKGG indicated that the mechanism of action might be related to the PI3K/AKT signaling pathway as well as the regulation of cell motility and cell migration. Molecular docking and pharmacokinetic analyses suggest that quercetin and isoprostanoid sterols may have therapeutic value and safety for EC. The in vitro experiments confirmed that GpM can inhibit EC cell proliferation, migration, and invasion and suppress PI3K and AKT phosphorylation. Conclusion: Our findings indicate that GpM exerts its anti-tumor effect on EC by inhibiting EC cell migration and invasion via downregulation of the PI3K/AKT signaling pathway. Hence, we have reason to believe that GpM could be a promising candidate for the treatment of EC.


  • Open Access

    Knockdown of Gas6 Exerts Anti-Esophageal Cancer Effects by Inhibiting the PI3K/AKT Pathway

    by Shuang Gao, Yu Wang, Ming Huang, Jianxin Guo, Zhongbing Wu, Jing Li

    Esophageal squamous cell carcinoma (ESCC) is a malignant tumor of the digestive tract with strong migratory and invasive abilities. Gas6 is closely associated with the progression of many malignant tumors; however, the role of Gas6 in the progression of esophageal cancer is unclear. Here, we report that the knockdown of Gas6 inhibited esophageal cancer cell proliferation, migration, and invasion. In addition, Gas6 knockdown downregulated the levels of P-PI3K and P-AKT. Taken together, the findings confirm that Gas6 knockdown can inhibit esophageal cancer progression and can exert anti-tumor effects on esophageal cancer through the PI3K/AKT pathway.


  • Open Access

    Therapeutic Potential of Terpenoids in Cancer Treatment: Targeting Mitochondrial Pathways

    by Jianxin Guo, Ming Huang, Shuang Hou, Jianfeng Yuan, Xiaoyue Chang, Shuang Gao, Zhenhan Zhang, Zhongbing Wu, Jing Li

    Background: In recent decades, natural compounds have been considered a significant source of new antitumor medicines due to their unique advantages. Several in vitro and in vivo studies have focused on the effect of terpenoids on apoptosis mediated by mitochondria in malignant cells.Recent findings: In this review article, we focused on six extensively studied terpenoids, including sesquiterpenes (dihydroartemisinin and parthenolide), diterpenes (oridonin and triptolide), and triterpenes (betulinic acid and oleanolic acid), and their efficacy in targeting mitochondria to induce cell death. Terpenoid‐induced mitochondria‐related cell death includes apoptosis, pyroptosis, necroptosis, ferroptosis, autophagy, and necrosis caused by mitochondrial permeability transition. Apoptosis and autophagy interact in meaningful ways. In addition, in view of several disadvantages of terpenoids, such as low stability and bioavailability, advances in research on combination chemotherapy and chemical modification were surveyed.Conclusion: This article deepens our understanding of the association between terpenoids and mitochondrial cell death, presenting a hypothetical basis for the use of terpenoids in anticancer management.